MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/21.03.25 Share Price

Warrant

DE000ME1GBG9

Market Closed - Börse Stuttgart 10:21:13 05/07/2024 pm IST
2.27 EUR +4.61% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/21.03.25
Current month-6.58%
1 month-0.44%
Date Price Change
05/24/05 2.27 +4.61%
04/24/04 2.17 +6.37%
03/24/03 2.04 -12.82%
02/24/02 2.34 -7.87%
01/24/01 2.54 +4.53%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 10:21 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1GBG
ISINDE000ME1GBG9
Date issued 03/10/2023
Strike 130 $
Maturity 21/03/2025 (259 Days)
Parity 10 : 1
Emission price 0.49
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.64
Lowest since issue 0.39
Delta0.71x
Omega 4.013
Premium9.09x
Gearing5.62x
Moneyness 1.095
Difference Strike -12.37 $
Difference Strike %-9.52%
Spread 0.01
Spread %0.43%
Theoretical value 2.335
Implied Volatility 34.89 %
Total Loss Probability 39.00 %
Intrinsic value 1.141
Present value 1.194
Break even 155.31 €
Theta-0.02x
Vega0.04x
Rho0.05x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus